针对NLRP3炎症酶作为骨关节炎的新型治疗点
Varnita Karmakar1, Mayukh Chain1, Ankit Majie1
1Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra, Ranchi, Jharkhand, 835215, India.
Inflammopharmacology
|January 13, 2025
概括
骨关节炎的治疗正在通过向NLRP3炎症酶,这是软骨损伤和炎症的关键驱动器,从而取得进展. 抑制这种途径对开发新型疗法来管理关节疼痛和硬有希望.
科学领域:
- 生物医学科学 生物医学科学
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
背景情况:
- 骨关节炎 (OA) 是一种流行,与年龄相关的关节疾病,导致软骨损失和炎症.
- 在OA中,疼痛,硬度和运动减少是由于矩阵金属蛋白酶和细胞因子生产的结果.
- 目前的OA治疗有局限性,这促使人们研究新的治疗点.
研究的目的:
- 审查将NLRP3炎症酶激活与骨关节炎发展联系在一起的机制性途径.
- 讨论针对NLRP3炎症酶治疗OA的新型治疗方法的进展.
主要方法:
- 临床前和临床研究的文献综述.
- 在OA中涉及NLRP3炎症酶的机制性途径的分析.
- 针对NLRP3.3的正在进行的研究和治疗开发的总结.
主要成果:
- 在OA进展中,NLRP3炎症酶失调至关重要.
- 抑制NLRP3可以调节MMP-13,酶-1和IL-1β等关键介质.
- 临床前和临床研究表明,NLRP3抑制对NLRP3有积极的反应.
结论:
- 准NLRP3炎症体为新型骨关节炎疗法提供了一个有希望的策略.
- 对NLRP3抑制剂的进一步研究可能会导致更有效的OA治疗方法.
相关概念视频
NF-κB-dependent Signaling Pathway
7.2K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.2K
The JAK-STAT Signaling Pathway
8.6K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.6K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
114
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
114


